显微镜下多血管炎
医学
肉芽肿伴多发性血管炎
血管炎
嗜酸性
蛋白酶3
抗中性粒细胞胞浆抗体
疾病
临床试验
病因学
ANCA相关性血管炎
重症监护医学
免疫学
内科学
病理
标识
DOI:10.1038/nrrheum.2014.104
摘要
In this Review of the clinical approach to treating patients with vasculitis, Cees G. M. Kallenberg summarizes the evolution of clinical diagnostic and classification criteria for the vasculitis syndromes. He argues that developments such as testing for ANCA specificity are the basis for a new approach to diagnosis and treatment of patients with AAV. The updated nomenclature for vasculitis defines this varied group of disorders by aetiology, specific features of pathogenesis and clinical symptoms; diagnostic and classification criteria for clinical practice are in development. Here, I review some important advances in the management of vasculitis within the category of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), which encompasses microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA). The clinical approach to the management of the patient with AAV should include testing for ANCA specificity; proteinase 3 (PR3)-specific ANCAs are most often associated with GPA, whereas myeloperoxidase (MPO)-ANCAs are usually associated with MPA. Also important to the management of AAV is an assessment of the disease stage and severity, to enable tailored treatment based on an algorithm derived from controlled-trial data. Remaining questions pertain to the dosage and duration of corticosteroid treatment, the selection of patients for, and duration of, maintenance treatment after induction of remission, and the identification of safer and more effective therapies than are currently in use. Outcome measures should assess not only disease activity, but also damage and quality of life. Infections, cardiovascular events and malignancies also contribute to outcome, and their prevention should therefore be part of the clinical approach to managing patients with AAV.
科研通智能强力驱动
Strongly Powered by AbleSci AI